A phase 3 trial is downgraded, and the second line now looks like the main focus for turmetabart adizutecan.

With a slashed valuation the newly listed biotech heads for phase 3.

SGN-CEACAM5C carries the same antibody as the discontinued tusamitamab ravtansine.

Padcev has eaten into bladder expectations, while a Tukysa trial has also gone.

An actinium-based backup and Werner helicase inhibitor are notable absences.

First-in-human listings bring a bispecific and yet another in vivo Car-T.